A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants.

Carteolol is a nonselective beta-blocker with intrinsic sympathomimetic activity (I.S.A.). A multicenter trial was started to check if the theoretical advantages of this new drug could also be confirmed in a clinical setting. The intraocular pressure (I.O.P.), the visual field and the adverse reactions were evaluated at day 8, 60, 360 and 960. The results of this study demonstrate that carteolol effectively lowers the I.O.P. with minimal adverse side effects in previously treated as well as untreated patients.